Anlon Healthcare Ltd approved the incorporation of two new subsidiaries on July 1, 2026, to expand its presence in the pharmaceuticals sector. The Board of Directors sanctioned the creation of Anlon Medicare Private Limited and Anlon Biologics Private Limited, alongside a proposal to rename an existing subsidiary. The company will invest an aggregate initial capital of up to ₹17.5 lakh to establish these entities, aiming to leverage growth opportunities in surgical implants and biological products.

The Board meeting, held at the company's registered office in Rajkot, approved the incorporation under Sections 2(87), 186, and other applicable provisions of the Companies Act, 2013. The decision aligns with the company's strategy to complement and expand its existing business in the pain management segment and other high-growth areas. Both subsidiaries will be incorporated in India, subject to approvals from the Registrar of Companies.

Anlon Healthcare will subscribe to the equity share capital of the proposed subsidiaries via cash consideration. For Anlon Medicare Private Limited, the company will subscribe to 55% of the equity share capital by investing up to ₹1,100,000 for 1,10,000 equity shares of ₹10 each. This entity will focus on manufacturing surgical implants and medical devices.

In the case of Anlon Biologics Private Limited, the company will acquire a 65% stake by investing up to ₹650,000 for 65,000 equity shares of ₹10 each. This subsidiary is being established to develop and manufacture peptides, biosimilars, and biological compositions. The company anticipates significant growth in this sector and aims to position itself to benefit from expanding opportunities.

Investment and Shareholding Details

The following table outlines the investment structure for the two newly approved subsidiaries:

Additionally, the Board approved changing the name of an existing subsidiary, Remember India Health Links Private Limited, to Anlon Medicos Private Limited. This change is subject to approval from the Ministry of Corporate Affairs. The intimation was submitted to the BSE Limited and the National Stock Exchange of India under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Anlon Healthcare reported a net profit of ₹354.69 lakh for the quarter ended June 30, 2025. The company recorded revenue from operations of ₹3,329.72 lakh for the first quarter of FY26. Total income for the period stood at ₹3,330.89 lakh, while total expenses were reported at ₹2,830.48 lakh.

The board of directors approved the unaudited standalone financial results at a meeting held on November 11, 2025. The results were reviewed by the Audit Committee prior to board approval. R V D & Co., Chartered Accountants, provided the Independent Auditor's Review Report, confirming that the financial statements were prepared in accordance with Indian Accounting Standard 34 (Ind AS 34).

Financial Performance

The company's profit before tax for the quarter was ₹500.41 lakh. Following a tax expense of ₹145.72 lakh, the profit after tax was finalized at ₹354.69 lakh. Basic and diluted earnings per equity share for the quarter were reported at ₹2.22.

Key Financial Metrics (Standalone)

Balance Sheet Highlights

As of June 30, 2025, the company's total assets stood at ₹19,775.76 lakh, an increase from ₹18,129.99 lakh as of March 31, 2025. Total current assets rose to ₹17,534.74 lakh from ₹15,848.09 lakh in the previous fiscal year end. Trade receivables increased to ₹9,365.71 lakh from ₹7,499.87 lakh.

On the liabilities side, total equity and liabilities reached ₹19,775.76 lakh. Current liabilities increased to ₹7,292.70 lakh as of June 30, 2025, compared to ₹6,005.22 lakh as of March 31, 2025. Borrowings, including current and non-current financial liabilities, were recorded at ₹5,842.07 lakh.